Chasing a Cure for GBM: Investigators Test Multiple Regimens in Novel Trial.
15 May 2020
Investigators of the first global adaptive phase 2/3 GBM Adaptive Global Innovative Learning Environment platform trial are implementing a multiarm, 2-stage approach to concurrently evaluate single-agent and combination regimens in glioblastoma.
Paxalisib will have its own trial design for the adaptive GBM AGILE trial.
https://www.onclive.com/view/chasing-a-cure-for-gbm-investigators-test-multiple-regimens-in-novel-trial
Regards.
Chasing a Cure for GBM: Investigators Test Multiple Regimens in...
Add to My Watchlist
What is My Watchlist?